Erratum to: High SARS-CoV-2 seroprevalence but no severe course of COVID-19 disease among people on opioid agonist treatment in Zurich: a cross-sectional study: Erratum to Swiss Med Wkly. 2022;152:w30122 (DOI 10.4414/smw.2022.w30122)

Swiss Medical Weekly

doi:10.4414/SMW.2022.w30149

Errata

Vol. 152 No. 0506 (2022)

Erratum to: High SARS-CoV-2 seroprevalence but no severe course of COVID-19 disease among people on opioid agonist treatment in Zurich: a cross-sectional study: Erratum to Swiss Med Wkly. 2022;152:w30122 (DOI 10.4414/smw.2022.w30122)

Swiss Medical Weekly

DOI: https://doi.org/10.4414/SMW.2022.w30149
Cite this as:: Swiss Med Wkly. 2022;152:w30149
Published: 01.02.2022

How to Cite

1.

Swiss Medical Weekly. Erratum to: High SARS-CoV-2 seroprevalence but no severe course of COVID-19 disease among people on opioid agonist treatment in Zurich: a cross-sectional study: Erratum to Swiss Med Wkly. 2022;152:w30122 (DOI 10.4414/smw.2022.w30122). Swiss Med Wkly [Internet]. 2022 Feb. 1 [cited 2024 Nov. 19];152(0506):w30149. Available from: https://smw.ch/index.php/smw/article/view/3155

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.